pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
EudraCT: 2008-004014-27
Phase 2 · other · Graft Versus Host Disease
EudraCT: 2008-004014-27 for Graft Versus Host Disease is a Phase 2 program (other) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Internal code EudraCT: 2008-004014-27
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lxo Ireland Designated Activity Company
- Phase
- Phase 2
- Modality
- other
- Indication
- Graft Versus Host Disease
- Status
- completed
- Trials
- 1